Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of IFN-γ on Innate Immune Cells

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02609932
Recruitment Status : Completed
First Posted : November 20, 2015
Last Update Posted : February 15, 2019
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
The investigators hypothesize that neutrophils and monocytes developed under the influence of Interferon- gamma-1b (IFN-γ-1b, Actimmune*) in vivo will display enhanced function across a broad range of activities related in large part to the transcriptional activation effects of this cytokine. The investigators will evaluate the effects of IFN-γ in healthy human subjects in vivo on gene expression, biologic activity markers, and functional activity of myeloid cells in single dose studies and in steady state studies.

Condition or disease Intervention/treatment Phase
Chronic Granulomatous Disease Drug: Administration of drug (Interferon-gamma 1-b) subcutaneously Phase 1

Detailed Description:
Named for their potent ability to interfere and protect against viral infections, interferons (IFNs) have many regulatory effects on the immune system.1 Of the members of the two classes of these compounds, IFN-γ has the most diverse and powerful immune effects. Studies have mostly evaluated IFN-γ interactions with cells of adaptive immunity, including macrophages and lymphocytes. Effects on innate immunity, particularly polymorphonuclear leukocytes or neutrophils and monocytes are less well studied. However, investigations have suggested that IFN-γ may be involved in signal transduction, gene expression, the respiratory burst and neutrophil NADPH oxidase (Nox2) activity, phagocytosis, motility, microbicidal activity, and apoptosis. Not all of these functions are enhanced by IFN-γ; but the clinical use of this cytokine has been driven, in part by these results. For example, the primary motivation for initiating investigation of its beneficial clinical effects in Chronic Granulomatous Disease (CGD) was its effects on Nox2 activity.2 Most data in this area was based on studies using differentiated neutrophils from peripheral blood.1 However, the phenotype of neutrophils developed under the influence of this cytokine, not just changes expressed by exposure of differentiated cells to IFN-γ, is critical to understanding the physiologic effects of IFN-γ and the broad applications for its use in treatment of a range of human diseases. To expand their understanding of the role of IFN-γ in the development and functional integrity of the neutrophil, the investigators have completed a series of studies with PLB-985 cells in an in vitro culture system of myeloid cells. In this proposal, the investigators will evaluate innate immune activation and phagocyte function in healthy adult volunteers who are receiving IFN-γ.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Effect of Interferon-gamma 1-b on Innate Immune Cells
Study Start Date : July 2016
Actual Primary Completion Date : August 2018
Actual Study Completion Date : February 2019


Arm Intervention/treatment
SD or SS
In this study, IFN- γ-1b will be subcutaneously administered a total of 30 subjects in one of two cohorts; Single Dose (SD) or Steady State (SS) dosing. Dosing of IFN- γ-1b will be based upon the time subject became eligible and started study. In this non-randomized, open-label study, subjects will be enrolled on the SD cohort first, and once that cohort has been filled, enrollment to the SS cohort will begin. Although not required, subjects in the SD cohort may also volunteer to participate in the SS cohort if they still meet eligibility criteria. Separate consents will be used for the SD and SS cohorts. In the event not all the SD subjects choose to continue onto the SS cohort, we will plan to recruit new participants from our local campus community.
Drug: Administration of drug (Interferon-gamma 1-b) subcutaneously
SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
Other Name: Actimmune




Primary Outcome Measures :
  1. Change in Neutrophil Nox2 activity. [ Time Frame: Determine the change in Nox2 activity at baseline compared to results for 8,24,48,72,96 hours after each IFN dose for the SD cohort. ]
    Nox2 activity will be measured by DHR oxidation or Sod inhibitable cytochrome c reduction.

  2. Change in Plasma IL-10 and Neuropterin concentration. [ Time Frame: Determine the change in IL-10 and neuropterin concentration at baseline compared to 4, 8, 12, 24, 36, 48, 72, and 96 hours after each IFN dose, SD cohort. ]
    IL-10nd Neuropterin will be measured by ELISA.

  3. Change in Neutrophil Gene Expression Analysis. [ Time Frame: Determine the change in gene expression at baseline compared to 4, 8, 12, 24, 36, 48, 72, and 96 hours after each IFN dose, SD cohort. ]
    RNA will be extracted and gene expression will be determined by Affimetrix Gene Chip assay.

  4. Change in IFN concentration and detection of anti-IFN antibody [ Time Frame: Determine the change in IFN level at baseline compared to 4, 8, 12, and 24 hours after administration of each dose of IFN-gamma in the SD cohort. Determine the change in IFN antibody at baseline compared to day 7-10 and day 30 after IFN ]
    IFN levels and anti-drug antibody will be completed by standard assays.


Secondary Outcome Measures :
  1. Change in Neutrophil Function studies. [ Time Frame: Determine the change in neutrophil function at baseline compared to results on Day 8 after the 4th dose of IFN. ]
    Neutrophil chemotaxis, bactericidal activity,ingestion, degranulation, f-Actin expression, CD11b/18 expression, Nox2 activity to a variety of agonists.

  2. Change in Anti-IFN antibody. [ Time Frame: Determine the change in IFN antibody at baseline compared to results for 7-10 da. and 30 da. after IFN. ]
    Anti-drug antibody to be determined by standard assay.

  3. Change in Monocyte function studies. [ Time Frame: Determine the change in monocyte function at baseline compared to results on Day 8 after the 4th dose of IFN. ]
    Monocyte chemotaxis, bactericidal activity,ingestion, Expression of monocyte specific surface determinants, CD11b/18 expression, Nox2 activity to a variety of agonists, cell content of specific proteins, and antibody dependent cellular cytotoxicity.

  4. Change in Neutrophil and Monocyte Gene Expression Analysis. [ Time Frame: Determine the change in monocyte function at baseline compared to results on Day 8 after the 4th dose of IFN. ]
    RNA will be extracted and gene expression will be determined by Affimetrix Gene Chip assay.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy adults over the age of 18 years up to 60 years.
  2. At time of screening subject is well and healthy;
  3. Acute infections resolved;
  4. Subject off treatment medications;
  5. No diagnosis of chronic conditions or active health care issues for which the subject is actively followed by a health care provider or is on chronic medications.
  6. Non-prescription medications for mild inter-current illnesses will be allowed at the discretion of the principal investigator.

Exclusion Criteria:

  1. Pregnancy.
  2. History of current infection;
  3. Two weeks from most recent intercurrent infection;
  4. History of recurrent infections or immunodeficiency.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02609932


Locations
Layout table for location information
United States, Colorado
University of Colorado Denver, Anschutz Medical Campus
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
Investigators
Layout table for investigator information
Principal Investigator: Daniel R. Ambruso, MD University of Colorado, Denver
Publications:
Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT02609932    
Other Study ID Numbers: 15-1643
UL1TR001082 ( U.S. NIH Grant/Contract )
First Posted: November 20, 2015    Key Record Dates
Last Update Posted: February 15, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of Colorado, Denver:
Interferon-gamma
innate immunity
Additional relevant MeSH terms:
Layout table for MeSH terms
Granulomatous Disease, Chronic
Phagocyte Bactericidal Dysfunction
Leukocyte Disorders
Hematologic Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Immunologic Deficiency Syndromes
Immune System Diseases
Interferons
Interferon-gamma
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents